AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 237 filers reported holding AMICUS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $333,184,000 | -3.2% | 27,400,000 | 0.0% | 5.20% | +11.3% |
| Q2 2023 | $344,144,000 | +13.7% | 27,400,000 | +0.4% | 4.67% | +4.0% |
| Q1 2023 | $302,757,000 | -7.5% | 27,300,000 | +1.9% | 4.49% | -8.2% |
| Q4 2022 | $327,228,000 | +17.0% | 26,800,000 | 0.0% | 4.89% | -5.4% |
| Q3 2022 | $279,792,000 | -2.8% | 26,800,000 | 0.0% | 5.17% | -9.1% |
| Q2 2022 | $287,832,000 | +48.3% | 26,800,000 | +30.7% | 5.69% | +60.5% |
| Q1 2022 | $194,135,000 | -9.1% | 20,500,000 | +10.8% | 3.54% | -2.6% |
| Q4 2021 | $213,675,000 | +26.6% | 18,500,000 | +4.6% | 3.64% | +37.1% |
| Q3 2021 | $168,837,000 | +40.7% | 17,679,273 | +42.0% | 2.65% | +27.0% |
| Q2 2021 | $120,018,000 | -0.8% | 12,450,000 | +1.6% | 2.09% | -0.1% |
| Q1 2021 | $121,030,000 | -41.8% | 12,250,000 | +36.1% | 2.09% | -41.6% |
| Q4 2020 | $207,810,000 | +35.6% | 9,000,000 | -17.1% | 3.58% | +64.4% |
| Q3 2020 | $153,202,000 | -7.6% | 10,850,000 | -1.4% | 2.18% | -33.6% |
| Q2 2020 | $165,880,000 | +63.9% | 11,000,000 | +0.5% | 3.28% | -4.0% |
| Q1 2020 | $101,178,000 | -7.3% | 10,950,000 | -2.2% | 3.42% | +6.6% |
| Q4 2019 | $109,088,000 | +22.5% | 11,200,000 | +0.9% | 3.20% | -13.7% |
| Q3 2019 | $89,022,000 | -28.7% | 11,100,000 | +11.0% | 3.71% | -13.9% |
| Q2 2019 | $124,800,000 | -3.4% | 10,000,000 | +5.3% | 4.31% | -22.8% |
| Q1 2019 | $129,200,000 | +33.2% | 9,500,000 | -6.2% | 5.59% | -3.6% |
| Q4 2018 | $96,998,000 | -14.0% | 10,125,000 | +8.5% | 5.80% | +11.9% |
| Q3 2018 | $112,838,000 | -22.9% | 9,333,132 | -0.4% | 5.18% | -8.0% |
| Q2 2018 | $146,346,000 | -0.3% | 9,369,150 | -21.0% | 5.63% | -19.6% |
| Q1 2018 | $146,722,000 | +38.1% | 11,855,547 | +35.3% | 7.01% | +1.7% |
| Q4 2017 | $106,279,000 | +0.8% | 8,763,122 | -7.1% | 6.89% | -15.8% |
| Q3 2017 | $105,472,000 | +75.0% | 9,437,122 | +52.7% | 8.18% | +7.5% |
| Q2 2017 | $60,257,000 | +73.3% | 6,180,956 | +21.3% | 7.61% | +71.3% |
| Q1 2017 | $34,769,000 | +74.1% | 5,097,577 | +26.9% | 4.44% | +10.1% |
| Q4 2016 | $19,967,000 | -26.9% | 4,017,577 | +8.9% | 4.03% | -15.8% |
| Q3 2016 | $27,305,000 | +35.2% | 3,689,857 | -0.2% | 4.79% | +6.8% |
| Q2 2016 | $20,195,000 | -30.2% | 3,698,665 | +8.0% | 4.49% | -55.5% |
| Q1 2016 | $28,934,000 | -15.2% | 3,424,104 | -2.6% | 10.09% | -14.1% |
| Q4 2015 | $34,101,000 | -42.6% | 3,515,611 | -17.3% | 11.75% | -24.0% |
| Q3 2015 | $59,460,000 | -8.5% | 4,250,199 | -7.4% | 15.46% | -13.6% |
| Q2 2015 | $64,951,000 | +41.8% | 4,590,199 | +9.0% | 17.89% | +1.7% |
| Q1 2015 | $45,820,000 | +95.0% | 4,211,399 | +49.1% | 17.58% | +10.5% |
| Q4 2014 | $23,497,000 | – | 2,824,185 | – | 15.92% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |